Bydd yr Aelodau'n ymwybodol o fanteision y brechlyn diweddaraf hwn sydd wedi cael cryn sylw – mae'n rhatach a bydd digon o gyflenwad ohono ond, yn hollbwysig, mae hefyd yn cyflwyno llawer llai o heriau logistaidd na brechlyn Pfizer/BioNTech, gan y gellir ei storio ar dymheredd oergell arferol. Felly, wrth i gapasiti'r GIG barhau i dyfu dros yr wythnosau nesaf, byddwn yn gallu cyflwyno'r brechlyn ble mae ei angen ym mhob rhan o Gymru. Bydd modelau cyflwyno symudol a llawer mwy hyblyg yn cael eu rhoi ar waith. Bydd pob cartref gofal o fewn cyrraedd a bydd y grŵp blaenoriaeth hwn yn ffocws allweddol i'r GIG dros yr wythnosau nesaf, fel y bydd y rhai dros 80 oed. Bydd y brechlyn newydd hefyd yn galluogi ymweliadau cartref â phobl sy'n gaeth i'r gwely, yr henoed a phobl sy'n agored i niwed, gan hwyluso'r gwaith o dargedu grwpiau blaenoriaeth eraill y bu'n anodd eu cyrraedd dros y mis diwethaf.
Members will be aware of the widely reported benefits of this latest vaccine – it is cheaper and supply will be more plentiful. However, crucially, it presents significantly fewer logistical challenges than the Pfizer/BioNTech vaccine, with storage at normal fridge temperatures. As NHS capacity continues to build over the coming weeks, we will be able to get the vaccine to where it is needed in every part of Wales. Much more flexible and mobile deployment models will be activated. Every care home will be within reach and this priority group will be a key focus for the NHS over the coming weeks, together with those aged over 80. The new vaccine will also enable home visits for our bed bound, elderly and vulnerable, facilitating the targeting of other priority groups that have been difficult to reach over the past month.